Non-drug Treatment Study in Parkinson's Disease Patients and Healthy Volunteers to Collect Biological Samples in Order to Assess ex Vivo the Activity of Candidate Therapies and Develop Novel Analytical Methods for Biomarkers

计划入组 45 人 · 首次发布于 2023 年 5 月 1 日

Fox BioNet Project: LRRK2-002

计划入组 114 人 · 首次发布于 2018 年 6 月 4 日

Chinese PD-LRRK2 Registry

计划入组 1,000 人 · 首次发布于 2018 年 5 月 14 日

LRRK2 Inhibitor(Lundbeck)

LRRK2 inhibitor(Interline Therapeutics)

LRRK2 inhibitor (Parkinson’s Disease)

Denali Therapeutics

United States

Corvus Pharmaceuticals

United States

Kura Oncology

United States

Montara Therapeutics Receives $3.3M Grant from Michael J. Fox Foundation to Develop Brain-Selective LRRK2 Inhibitor for Parkinson's

Halia Therapeutics Doses First Healthy Volunteer with Oral LRRK2 Inhibitor HT-4253 for Alzheimer's

Halia Therapeutics Presents LRRK2 Inhibitor HT-4253 for Neurodegenerative Diseases at BIO Investor Forum